Listed Canadian company delivers 475% more CBD to the bloodstream
If Kim Kardashian is spruiking the benefits of cannabinoids (CBD), you know its influence is growing.
Kim Kardashian’s CBD Baby Shower featured a number of Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) CBD+ wellness products.
The baby shower was a curated CBD themed party designed to provide guests a soothing, relaxing holistic health experience.
“I am freaking out so much, I just want a Zen-like CBD-themed baby shower,” Kardashian told E! News when asked about the theme for the party.
Kardashian’s CBD-based baby shower experience was curated by HelloMD to create an experiential CBD wellness event including a selection of Wildflower products. A variety of treatments featured at the baby shower included a Wildflower CBD+ Pure tincture infused tea station; Wildflower CBD+ Pure tincture infused beverages at the bar; enjoyment of Wildflower’s CBD+ Aches blend Vaporizer before a sound bath; and a CBD bar where guests made their own infused oils and bath salts.
Celebrity baby shower aside, there are various listed companies making big moves in the cannabis wellness space.
A supreme acquisition
The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) and Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B:GR) announced that they have entered into a definitive arrangement agreement that will see Supreme Cannabis acquire all of the issued and outstanding common shares of Blissco not already owned by Supreme Cannabis.
The Arrangement is an all-stock transaction with a total value of approximately C$48 million (AU$51.7).
"Supreme Cannabis is the best positioned company in the cannabis space to help Blissco achieve its ambition of delivering innovative, quality assured full-spectrum cannabis products to the world," said Damian Kettlewell, CEO of Blissco.
"By merging with Supreme Cannabis, Blissco shareholders will benefit from the combined expertise of both companies in growing premium cannabis brands, producing and procuring high-quality inputs, commercializing new products, and ensuring regulatory compliance. Blissco shareholders will also benefit from Supreme Cannabis' enhanced trading liquidity on the TSX and greater access to capital that will allow us to focus and accelerate Blissco's premium wellness business."
"Blissco has built a distinct and authentic premium wellness brand. Through our strategic partnership and prior investment in the company, we developed a deep understanding of the business and a high level of confidence in the senior management team. This transaction will allow Blissco to focus its business around the production and commercialization of cannabis oils and topicals for the premium wellness consumer," said Navdeep Dhaliwal, CEO of Supreme Cannabis.”
More CBD to the bloodstream
Perhaps the biggest news this week features Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a company which has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules.
Lexaria has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil, a commonly used medium chain triglyceride (MCT) oil in the cannabis edibles industry.
On March 20, 2019, Lexaria announced it had commenced a series of animal studies with multiple objectives, including gaining a better understanding of how edible forms of cannabinoids enter the bloodstream.
Here is an in-depth examination of the testing.
MCT oils are commonly used by many firms making and selling cannabis edibles throughout North America.
Lexaria has consistently said that the use of MCT oil in edibles is less effective for purposes of cannabinoid delivery optimization than its patented DehydraTECH LCFA formulations. Although these studies tested only for CBD delivery, Lexaria believes that virtually identical results would have been achieved if THC was instead the cannabinoid under examination, consistent with subjective human clinical studies Lexaria's partners have conducted with edible THC products.
The cannabis edibles industry has partially embraced the use of MCT oils such as coconut oils as a co-ingredient in edible products, mostly because of the luxurious taste and mouth-feel of coconut oil. Lexaria's head-to-head animal absorption study has proven that coconut oil formulations deliver cannabinoids into animal bloodstreams very poorly at only about one-quarter the rate of the patented Lexaria LCFA formulation. Lexaria's DehydraTECH technology was also shown to deliver CBD considerably more quickly than MCT oil formulations.
The final word
While the Kardashians are playing their role in normalising CBD use, celebrity endorsement is just one facet of what is significant activity in this growing sector.
The science is expanding. And with that, we should see some exciting developments in the industry in the back half of 2019.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.